Cardiovascular Research 2024
Inhibition of oxidized low-density lipoprotein with orticumab inhibits coronary inflammation and reduces residual inflammatory risk in psoriasis: a pilot randomized, double-blind placebo-controlled trial | Farina et al.
JAMA Cardiology 2019
Association of Biologic Therapy with Coronary Inflammation in Patients with Psoriasis as assessed by Perivascular Fat Attenuation Index | Elnabawi et al.
European Heart Journal 2020
Imaging Residual Inflammatory Cardiovascular Risk | Antoniades et al
JACC 2023
Pericoronary Adipose Tissue as a Marker of Cardiovascular Risk | Tan et al.
